ESTUDO COMPARATIVO DA EFICACIA DO ETANOL E ACIDO L-GLUTAMICO NA PREVENÇAO DA CALCIFICAÇAO DAS CUSPIDES E PAREDE AORTICA PORCINA. ESTUDO EXPERIMENTAL EM RATOS

(especial para SIIC © Derechos reservados)
Concluiu-se que o pré-tratamento com etanol a 80% inibiu a calcificação nas cúspides aórticas porcinas, entretanto não teve a mesma eficácia na parede aórtica
soncini9.jpg Autor:
George ronald Soncini da rosa
Columnista Experto de SIIC

Institución:
Departamento de posGarduación en Clínica Quirúrgica Hospital de Clínicas Universidad Federal do Paraná


Artículos publicados por George ronald Soncini da rosa
Coautor
Francisco Diniz Affonso Da Costa* 
Doutor em Clínica Cirúrgica pela Universidade Federal do Paraná; Professor Adjunto em Técnica operatória no curso de Medicina PUC-PR; Membro titular pela Sociedade Brasileira de Cirurgia Cardiovascula*
Recepción del artículo
31 de Enero, 2005
Aprobación
22 de Febrero, 2005
Primera edición
30 de Agosto, 2005
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Introdução: As cúspides porcinas tratadas com glutaraldeído (GDA) são um dos tecidos biológicos mais utilizados em biopróteses, porém a calcificação tardia pós-implante constitui a causa predominante de sua falência. Objetivo: Analisar comparativamente dois métodos de prevenção da calcificação (etanol 80% e ácido L-glutâmico 0.8%) em cúspide e parede aórtica porcina implantadas no subcutâneo em ratos, tendo como grupo controle as cúspides e os segmentos de parede aórtica fixadas em glutaraldeído (GDA), num período de 15, 30 e 60 dias após implante. Métodos: Foram utilizados 45 ratos jovens, distribuídos em 3 grupos contendo 15 animais cada, que por sua vez foram subdivididos em 3 subgrupos de 5 animais, nos quais foram implantados, em 2 bolsas no subcutâneo, uma cúspide e um segmento de parede aórtica em cada. Em cada grupo assim nominados: GDA (grupo controle), E80% (grupo cuja as estruturas foram pré-tratadas com etanol 80%) e o AG 0.8% (grupo cuja as estruturas foram pré-tratadas com ácido L-glutâmico 0.8%) foram realizadas a mensuração do cálcio e análise microscópica quanto à presença de calcificação: localização e intensidade da mesma; Infiltrado inflamatório: localização e tipo, no período de 15, 30 e 60 dias após implante. Resultados: Na mensuração do cálcio na cúspide aórtica encontrou-se no grupo E80% 15 dias (1.30 ± 0.21 μg cálcio/mg tecido), E80% 30 dias (1.05 ± 0.22 μg cálcio/mg tecido) e E80% 60 dias (0.53 ± 0.42 μg cálcio/mg tecido); no grupo AG 0.8% 15 dias (12.17 ± 0.66 μg cálcio/mg tecido), AG 0.8% 30 dias (15.31 ± 2.82 μg cálcio/mg tecido) e AG 0.8% 60 dias (34.24 ± 16.28 μg cálcio/mg tecido) com o grupo controle GDA 15 dias (12.44 ± 2.26 μg cálcio/mg tecido), GDA 30 dias (13.44 ± 3.34 μg cálcio/mg tecido) e GDA 60 dias (50.85 ± 8.71 μg cálcio/mg tecido). Em relação à mensuração do cálcio na parede aórtica, encontrou-se no grupo de E80% 15 dias (4.62 ± 0.68 μg cálcio/ mg tecido), E80% 30 dias (9.47 ± 2.59 μg cálcio/mg tecido) e E80% 60 dias (23.56 ± 7.75 μg cálcio/mg tecido) no grupo de AG 0.8% 15 dias (4.31 ± 0.85 μg cálcio/mg tecido), AG 0.8% 30 dias (7.69 ± 1.48 μg cálcio/mg tecido) e AG 0.8% 60 dias (20.50 ± 1.22 μg cálcio/mg tecido) com o grupo controle GDA 15 dias (7.34 ± 1.32 μg cálcio/mg tecido), GDA 30 dias (9.28 ± 0.76 μg cálcio/mg tecido) e GDA 60 dias (27.60 ± 1.08 μg cálcio/mg tecido). Na avaliação microscópica da cúspide aórtica houve uma progressiva calcificação naquelas submetidas a fixação com GDA. Esse processo foi parcialmente encontrado com o AG 0.8% e totalmente ausente com o E80%. Quanto à avaliação referente aos segmentos da parede aórtica, também evidenciou-se progressiva calcificação, não sendo inibidas pelos tratamentos com AG 0.8% e E80%. Conclusões: Concluiu-se que o pré-tratamento com etanol a 80% inibiu a calcificação nas cúspides aórticas porcinas, entretanto não teve a mesma eficácia na parede aórtica. Contudo, o ácido L-glutâmico a 0.8% demonstrou minimizar a calcificação na parede aórtica. Estudos devem ser feitos para evidenciar se a ação anticalcificante do etanol a 80% mantém-se em as biopróteses aórticas porcinas forem implantadas no sistema circulatório.

Palabras clave
Cúspide porcina, etanol, calcificação, parede aórtica porcina, ácido L-glutâmico


Artículo completo

(castellano)
Extensión:  +/-8.12 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Introduction: The glutataldehyde (GDA) treated pigs cusps are one of most employed tissues in bioprothesis, but its late post-implant calcification is the main cause of its failure. Background: This study aims at comparing and analyzing two methods (ethanol 80% and l-glutamic acid 0.8%) to prevent calcification in pig cusps and aortic wall implanted subcutaneously in rats, the cusps and aortic wall segments of the controls were fixed with glutaraldehyde (GDA), during a 15, 30 and 60 days after the implant. Material and Methods: We used 45 young rats, distributed in 3 groups of 15 rats each, which were subdivided in 3 subgroups of 5 rats each, in which we implanted one cusp and one aortic wall segment in 2 subcutaneous pouches for each rat. We called each group as follows: GDA (control group), E80% (the group whose structures were previously prepared with ethanol 80%) and GA 0.8% (group previously prepared with L-glutamic acid 0.8%); in those groups we measured calcium and performed a microscopic analysis seeking for any calcification, its location and intensity; inflammatory infiltrate, location and type, during a 15, 30. and 60-day period after the implant. Results: Calcium was found in the aortic cusp in the E80% group (1.30 ± 0.21 μg calcium/mg tissue) at day 15, (1.05 ± 0.22 μg calcium/mg tissue) at day 30. and (0.53 ± 0.42 μg calcium/mg tissue) at day 60; in the GA 0.8% group (12.17 ± 0.66 μg calcium/mg tissue) at day 15, (15.31 ± 2.82 μg calcium/mg tissue) at day 30. and (34.24 ± 16.28 μg calcium/mg tissue) at day 60; and in the control group, GDA at day 15 (12.44 ± 2.26 μg calcium/mg tissue), at day 30 (13.44 ± 3.34 μg calcium/mg tissue), and at day 60 (50.85 ± 8.71 μg calcium/mg tissue). As for the calcium measured in the aortic wall, in the E80% group we found (4.62 ± 0.68 μg calcium/mg tissue) at day 15, (9.47 ± 2.59 μg calcium/mg tissue) at day 30. and (23.56 ± 7.75 μg calcium/mg tissue) at day 60; in the GA 0.8% group at day 15 (4.31 ± 0.85 μg calcium/mg tissue), at day 30 (7.69 ± 1.48 μg calcium/mg tissue), and at day 60 (20.50 ± 1.22 μg calcium/mg tissue); and in the control group (GDA) at day 15 (7.34 ± 1.32 μg calcium/mg tissue), at day 30 (9.28 ± 0.76 μg calcium/mg tissue), at day 60 (27.60 ± 1.08 μg calcium/mg tissue). Microscopic evaluation of the aortic cusp, showed a progressive calcification in those fixed with GDA. Such process was found partially in the GA 0.8% group, and totally absent in the E80% group. As for the assessment of the aortic wall segments, we also observed progressive calcification, which was not inhibited by the treatment with either GA 0.8% or E80%. Conclusions: We concluded that a pre-treatment with ethanol at 80% inhibited calcification in pig aortic cusps, however it was not as effective on the aortic wall. However, L-glutamic acid at 0.8% did show that it minimizes calcification in the aortic wall. Further studies are required, to demonstrate if the anti-calcifying action of ethanol at 80% is kept if the pig aortic bioprostheses are implanted in the circulatory system.

Key words
Descriptors: pig aortic cusp, calcification, ethanol, pig aortic wall, l-glutamic acid


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Cardiología
Relacionadas: Medicina Interna



Comprar este artículo
Extensión: 8.12 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra




Patrocinio y reconocimiento:
Trabalho realizado no Departamento de Cirurgia Experimental da Disciplina de Técnica Operatória da Pontifícia Universidade Católica do Paraná (PUC-PR), Curitiba, PR, Brasil
Bibliografía del artículo
  1. Schoen FJ, Levy RJ. Current challenges and future research perpectives. Founder’s Award, 25th Annual Meeting of the Society for Biomaterials, Providence, RI, April 28-May 2, 1999. Tissue Heart Valves: 1999; 439-465.
  2. Cosgrove DM. Valve reconstruction versus valve replacement. In: Current hearth valve prostheses. In: Crawford FA ed. Cardiac Surgery. 1987; 143 p.
  3. Gott JP et al. Calcification of porcine valves: a successful new method of antimineralization. Ann Thorac Surg, 1992; 53:207-216.
  4. Ross D. Homograft replacement of the aortic valve. Lancet, 1962; 2:487.
  5. Ionescu MI, Wooler GH, Smith DR, Grinshaw VA. Mitral valve replacement with aortic heterografts in humans. Thorax, 1967; 22:305-313.
  6. Braile DM et al. Experiência inicial com emprego das próteses de Lillehei-Kaster. Arq Bras Cardiol, 1974; 27 (supl. 1):14.
  7. Puig LB, Verginelli G. Válvulas cardíacas de dura-máter homóloga. Nota prévia. R Paul Med, 1971; 78:33–35.
  8. Potkin BN et al. Bioprostheses in tricuspid and mitral valve positions for 95 months with heavier calcific deposits on the right-sided valve. Am J Cardiol, 1988; 61:947-949.
  9. Carpentier A et al. Remplancement des valvules mitraes et ki cuspides per le’tirogreffes. Ann Clin Thorac Cardiovasc, 1968; 7:33-38.
  10. Pelletier L et al. Porcine versus pericardial bioprotheses: a comparision of late results in 1,593 patients. Ann Thorac Surg, 1989; 47:352-361.
  11. Barratt-Boyes BG. Homograft aortic valve replacement in aortic incompetence and stenosis. Thorax, 1964; 19:131.
  12. Carpentier A et al. Six-year follow-up of glutaraldehyde-preserved heterografts: with particular reference to the treatment of congenital valve malformations. J Thorac Cardiovasc Surg, 1974; 68:771-782.
  13. Carpentier A et al. Techniques for prevention of calcification of valvular bioprostheses. Circulation, 1984; 70 (suppl 1):165-168.
  14. Aupart RM et al. The last generation of pericardial valves in the aortic position. Ann Thorac Surg, 1996; 6:615-620.
  15. Jamieson WR et al. Carpentier-Edwards standard porcine bioprosthesis: clinical performance to seventeen years. Ann Thorac Surg, 1995; 60:999-1007.
  16. Scheld HH, Konertz W. The pathology of bioprosthetic heart valves and allografts. Curr Top Pathol, 1994; 86:87-125.
  17. Grunkemeier GL, Bodnar E. Comparative assessment of bioprosthesis durability in the aortic position. J Hearth Valve Dis, 1995; 4:49-55.
  18. Vyavahare N et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation, 1997; 95:479-488.
  19. Lee CH et al. Inhibition of aortic wall calcification in bioprosthetic hearth valves by ethanol pretreatment: Biochemical and biophysical mechanism. J Biomed Mater Res, 1998; 42:30-37.
  20. Vyavahare NR et al. Prevention of glutaraldehyde - fixed bioprosthetic heart valve calcification by alcohol pretreatment: further mechanistic studies. J of Heart Valve Disease, 2000; 9:561-566.
  21. Shen M et al. Effect of ethanol and ether in the prevention of calcification of bioprostheses. Ann Thorac Surg, 2001; 71:413-416.
  22. Schoen FJ et al. Biomaterial-associated calcification: pathology, mechanisms, and strategies for prevention. J Biomed Mater Res, 1988; 22:11-36.
  23. Golomb G et al. The role of glutaraldehyde - induced cros-links in calcification of bovine pericardium used in cardiac valve bioprotheses. Am J Pathol, 1987; 127:122-130.
  24. Grimm M, Eybl E, Grabenwoger M. Biocompatibility of aldehyde - fixed bovine pericardium. J Thorac Cardiovasc Surg, 1991; 102:195-201.
  25. Grabenwoger M et al. Decreased tissue reaction to bioprosthetic heart valve material after L-glutamic acid treatment: a morphological study. J Biomed Mater Res, 1992; 26:1231-1240.
  26. Carpentier A et al. Biological factors affecting long-term results of valvular hetero-grafts. J Thorac Cardiovasc Surg, 1969; 58:467-483.
  27. Grunkemeier GL et al. Actuarial versus actual risk of porcine structural valve deterioration. J Thorac Cardiovasc Surg, 1994; 108:709-718.
  28. Milano A et al. Valve-related complications in eldery patients with biological and mechanical aortic valves. Ann Thorac Surg, 1998; 66:S82-S87.
  29. Hirsch D et al. Synergistic inhibition of the calcification of glutaraldehyde pretreated bovine pericardium in rat a subdermal model by FeCI3 and ethanehydroxydisphosphonate: preincubation and polymeric controlled release studies. Biomaterials, 1993; 14:705-711.
  30. Jones M et al. The effects of anticalcification treatments on bioprosthetic heart valves implanted in sheep. Trans Am Soc Artif Intern Organs, 1988; 34:1027-1030.
  31. Chen W, Schoen FJ, Levy RJ. Mechanism of efficacy of 2-amino oleic acid for inhibition of calcification of glutaraldehyde-pretreated porcine bioprosthetic heart valves. Circulation, 1994a; 90:323-329.
  32. Chen W, Kim JD, Schoen FJ, Levy RJ. Effect of 2-amino oleic acid exposure conditions on the inhibition of calcification of glutaraldehyde crosslinked porcine aortic valves. J Biomed Mater Res, 1994b; 28:1485-1495.
  33. Hirsch D et al. Inhibition of calcification of glutaraldehyde pretreated porcine aortic valve cusps with sodium dodecyl sulfate: preincubation and controlled release studies. J Biomed Mater Res, 1993; 27:1477-1484.
  34. Levy RJ, Schoen FJ, Lund SA, Smith MS. Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy: experimental studies of optimal dosages and therapeutic durations. J Thorac Cardiovasc Surg, 1987; 94:551-557.
  35. Levy RJ et al. Inhibition of calcification of bioprosthetic heart valves by local controlled-released diphosphonate. Science, 1985; 228:190-192.
  36. Vyavahare N et al. Synergism of calcium-ethanehydroxybisphosphonate (CaEHBP) and FeCL3: controlled release polymers for preventing calcification of bioprosthetic aortic. J Control Rel, 1995; 34:34-97.
  37. Webb CL, Schoen FJ, Levy RJ - Covalent binding of aminopropanehydroxydisphosphonate to glutaraldehyde residues in pericardial bioprosthetic tissue. Exp Mol Pathol, 1989; 50:291-302.
  38. Jones M et al. Anticalcification treatments of bioprosthetic heart valves: in vivo studies in sheep. J Cardiac Surg, 1989; 4:69-73.
  39. Golomb G, Ezra V. Prevention of bioprosthetic heart valve tissue calcification by charge modification: effects of protamine binding by formaldehyde. J Biomed Mat Res, 1991; 15:85-98.
  40. Schoen FJ, Levy RJ. Pathophysiology of bioprosthetic heart valve calcification. In: Bodnar, E. Yacoub, M.H. ed. Biological and bioprosthetic valves. New York: 1986. 418-429p.
  41. Schoen FJ, Hirsch D, Bianco RW, Levy RJ. Onset and progression of calcification in porcine aortic bioprosthetic valves implanted as orthotopic mitral valve replacements in juvenile sheep. J Thorac Cardiovasc Surg, 1994; 108:880-887.
  42. Weissenstein C, Human P, Bezuidenhout D, Zilla P. Glutaraldehyde detoxification in addition to enhanced amine cross-linking dramatically reduces bioprosthetic tissue calcification in the rat model. J Heart Valve Dis, 2000; 9:230-240.

 
 
 
 
 
 
Clasificado en
Artículos originales>
Expertos del Mundo

Especialidad principal:
Cardiología


Relacionadas:
Medicina Interna
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008